Talus Bio Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
27
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
47
Talus Bio General Information
Description
Developer of a data-enabled drug development platform designed to offer small-molecule therapy in oncology. The company's platform combines cell processing with high-sensitivity quantitative proteomics and machine learning analytics, focusing on drug discovery through gene regulation, enabling the healthcare sector to advance drug development for gene control.
Contact Information
Website
www.talus.bioCorporate Office
- 550 17th Avenue
- Suite 550
- Seattle, WA 98122
- United States
Corporate Office
- 550 17th Avenue
- Suite 550
- Seattle, WA 98122
- United States
Talus Bio Timeline
Talus Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 15. Accelerator/Incubator | 21-Sep-2026 | Completed | Pre-Clinical Trials | |||
| 14. Seed Round | 20-Aug-2024 | Completed | Pre-Clinical Trials | |||
| 13. Grant | 01-Feb-2024 | Completed | Pre-Clinical Trials | |||
| 12. Grant | 20-Sep-2023 | Completed | Pre-Clinical Trials | |||
| 11. Grant | 01-Jul-2023 | Completed | Pre-Clinical Trials | |||
| 10. Grant | 01-Apr-2023 | Completed | Pre-Clinical Trials | |||
| 9. Seed Round | 07-Jun-2022 | Completed | Pre-Clinical Trials | |||
| 8. Grant | 06-Jun-2022 | Completed | Pre-Clinical Trials | |||
| 7. Grant | 01-Apr-2022 | $790K | $1.51M | Completed | Pre-Clinical Trials | |
| 6. Accelerator/Incubator | 01-Jan-2022 | $1.51M | Completed | Pre-Clinical Trials |
Talus Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed Plus | ||||||||
| Seed-4 | ||||||||
| Seed-3 | ||||||||
| Seed-2 | 317,661 | $0.000100 | 8% | $0.79 | $0.79 | 1x | $0.74 | 0.73% |
| Seed-1 | 7,632,793 | $0.000100 | 8% | $0.87 | $0.87 | 1x | $0.79 | 18.18% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Talus Bio Comparisons
Industry
Financing
Details
Talus Bio Competitors (68)
One of Talus Bio’s 68 competitors is Foghorn Therapeutics, a Formerly VC-backed company based in Watertown, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Foghorn Therapeutics | Formerly VC-backed | Watertown, MA | ||||
| Vir Biotechnology | Formerly VC-backed | San Francisco, CA | ||||
| etherna | Formerly VC-backed | Niel, Belgium | ||||
| PEP-Therapy | Venture Capital-Backed | Evry Cedex, France | ||||
| Histogen | Formerly VC-backed | San Ramon, CA |
Talus Bio Patents
Talus Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260226097-A1 | Extraction of nuclear and chromatin-bound proteins using volatile salts | Pending | 03-Feb-2023 | ||
| WO-2024163959-A2 | Extraction of nuclear and chromatin-bound proteins using volatile salts | Inactive | 03-Feb-2023 | ||
| WO-2024163959-A3 | Extraction of nuclear and chromatin-bound proteins using volatile salts | Inactive | 03-Feb-2023 | ||
| EP-4658665-A2 | Lectin-assisted isolation of mammalian cell nuclei | Pending | 03-Feb-2023 | ||
| US-20260242771-A1 | Lectin-assisted isolation of mammalian cell nuclei | Pending | 03-Feb-2023 | C12N15/1013 |
Talus Bio Signals
Talus Bio Investors (47)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Plug and Play | Accelerator/Incubator | |||
| Funders Club | Angel Group | Minority | ||
| Gaingels | Venture Capital | Minority | ||
| Two Bear Capital | Venture Capital | Minority | ||
| WRF Capital | Corporate Venture Capital | Minority |
Talus Bio FAQs
-
When was Talus Bio founded?
Talus Bio was founded in 2020.
-
Where is Talus Bio headquartered?
Talus Bio is headquartered in Seattle, WA.
-
What is the size of Talus Bio?
Talus Bio has 27 total employees.
-
What industry is Talus Bio in?
Talus Bio’s primary industry is Drug Discovery.
-
Is Talus Bio a private or public company?
Talus Bio is a Private company.
-
What is Talus Bio’s current revenue?
The current revenue for Talus Bio is .
-
How much funding has Talus Bio raised over time?
Talus Bio has raised $19.6M.
-
Who are Talus Bio’s investors?
Plug and Play, Funders Club, Gaingels, Two Bear Capital, and WRF Capital are 5 of 47 investors who have invested in Talus Bio.
-
Who are Talus Bio’s competitors?
Foghorn Therapeutics, Vir Biotechnology, etherna, PEP-Therapy, and Histogen are some of the 68 competitors of Talus Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process